InspireMD has completed the first phase of a manufacturing consolidation that the company believes will improve its long term gross margins. Simultaneously, the company has signed an agreement with HealthLink Europe to provide logistical and customer support for InspireMD's commercial operations and clinical activities. HealthLink will provide InspireMD with customer service centre capabilities for inquiries from hospitals and distributors. HealthLink will also handle all inventory controls, warehousing, shipping, and invoicing and receivables management for customers worldwide on behalf of InspireMD.
InspireMD has successfully completed the first stage of its manufacturing strategy through the consolidation of its Israeli manufacturing facilities. Over time, the company believes that this will reduce its operating costs by streamlining its manufacturing operations.
As InspireMD prepares to announce the 12-month results from the MASTER trial in October, the company continues to put in place the appropriate infrastructure to be able to meet the anticipated increase in demand for its MGuard stent technology. The agreement with HealthLink is intended to support both current commercial activities as well as ongoing clinical trials, and should provide InspireMD instant access to customer logistics to support all of the company's customers through a single partner. The MGuard embolic protection stent (EPS) is integrated with a precisely engineered micro net mesh that prevents the unstable arterial plaque and thrombus that caused the myocardial infarction blockage from breaking off. MGuard EPS is CE marked. Currently, it is not approved for sale in the US.